13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001856083
Total reported value
$6.9B
$6.9B
69 檔
10.6%
During the Q3 2024 filing period, Deep Track Capital, LP (CIK: 0001856083) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $6.9B across 69 reported positions.
Deep Track Capital, LP executed strategic sector rebalancing during Q3 2024, establishing 11 new positions while fully exiting 10 holdings and trimming 22 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 6.28% | — | -8.75% | |
| 2 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.43% | — | +14.92% | |
| 3 | GH | Guardant Health Inc | Stock-Healthcare | 4.37% | +2.37% | +33.35% | |
| 4 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 4.03% | -2.98% | EXIT | |
| 5 | IMVT | Immunovant Inc | Stock-Other | 3.93% | +0.56% | +50.76% | |
| 6 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 3.91% | — | +3.89% | |
| 7 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.74% | -0.11% | -17.95% | |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.72% | — | +4.08% | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.51% | +0.09% | — | |
| 10 | NTLA | Intellia Therapeutics Inc | Stock-Other | 3.23% | — | +3.13% | |
| 11 | ALKS | Alkermes plc | Stock-Healthcare | 3.11% | +0.98% | — | |
| 12 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.01% | -0.55% | -42.94% | |
| 13 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 2.90% | — | -20.50% | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.80% | +0.15% | +10.00% | |
| 15 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.76% | +1.12% | -3.09% | |
| 16 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.71% | +0.51% | -4.41% | |
| 17 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 2.55% | — | +1.65% | |
| 18 | MBX | Mbx Biosciences Inc | Stock-Other | 2.49% | +0.05% | — | |
| 19 | PLRX | Pliant Therapeutics Inc | Stock-Other | 2.12% | — | — | |
| 20 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.86% | -0.39% | EXIT | |
| 21 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.76% | — | — | |
| 22 | GPCR | Structure Therapeutics Inc | Stock-Other | 1.70% | +0.33% | +28.47% | |
| 23 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.51% | +0.27% | NEW | |
| 24 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.48% | -0.92% | EXIT | |
| 25 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.40% | — | +0.86% | |
| 26 | ABVX | Abivax Sa-adr | Stock-Other | 1.31% | — | -14.37% | |
| 27 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 1.28% | — | -39.90% | |
| 28 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 1.28% | — | +15.75% | |
| 29 | KURA | Kura Oncology Inc | Stock-Other | 1.22% | -0.03% | +410.32% | |
| 30 | GERN | Geron CORP | Stock-Other | 1.09% | -0.77% | EXIT | |
| 31 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.05% | -0.61% | +375.42% | |
| 32 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.96% | +1.04% | — | |
| 33 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 0.96% | -0.75% | EXIT | |
| 34 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.93% | — | -43.07% | |
| 35 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.93% | — | +490.46% | |
| 36 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.90% | — | -59.98% | |
| 37 | KRRO | Korro Bio Inc | Stock-Other | 0.90% | — | +10.30% | |
| 38 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.69% | — | — | |
| 39 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.68% | -2.05% | EXIT | |
| 40 | ALEC | Alector Inc | Stock-Other | 0.68% | — | — | |
| 41 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.66% | — | -10.92% | |
| 42 | ETNBGBP | 89bio Inc | Stock-Other | 0.65% | — | +20.60% | |
| 43 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.64% | +0.45% | — | |
| 44 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 45 | FATE | Fate Therapeutics Inc | Stock-Other | 0.62% | — | — | |
| 46 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.58% | — | -26.46% | |
| 47 | ✓ | Engene Holdings Inc | Stock-Other | 0.55% | -0.49% | EXIT | |
| 48 | EDIT | Editas Medicine Inc | Stock-Other | 0.53% | — | -18.33% | |
| 49 | XNCR | Xencor Inc | Stock-Other | 0.51% | +0.14% | NEW | |
| 50 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.49% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MBX | Mbx Biosciences Inc | +2.5% | NEW | New buy |
| 2 | IMVT | Immunovant Inc | +1.7% | +50.76% | Add |
| 3 | VRDN | Viridian Therapeutics Inc | +1.2% | -4.41% | Trim |
| 4 | VRNA | Verona Pharma PLC - Adr | +1.2% | -20.50% | Trim |
| 5 | APLSUSD | Apellis Pharmaceuticals Inc | +1.2% | +76.03% | Add |
| 6 | ARGX | Argenx Se - Adr | +1.2% | -8.75% | Trim |
| 7 | KURA | Kura Oncology Inc | +1% | +410.32% | Add |
| 8 | ORKA | Oruka Therapeutics Inc | +1% | NEW | New buy |
| 9 | OCUL | Ocular Therapeutix Inc | +0.9% | — | Unchanged |
| 10 | CYTK | Cytokinetics Inc | +0.8% | +375.42% | Add |
| 11 | EWTX | Edgewise Therapeutics Inc | +0.8% | +490.46% | Add |
| 12 | DVAX | Dynavax Technologies CORP | +0.8% | +14.92% | Add |
| 13 | RNAGBP | Avidity Biosciences Inc | +0.7% | NEW | New buy |
| 14 | APGE | Apogee Therapeutics Inc | +0.7% | — | Unchanged |
| 15 | 260 | Centessa Pharmaceuticals-adr | +0.7% | NEW | New buy |
| 16 | BCAX | Bicara Therapeutics Inc | +0.6% | NEW | New buy |
| 17 | AKRO | Akero Therapeutics Inc | +0.6% | NEW | New buy |
| 18 | GPCR | Structure Therapeutics Inc | +0.6% | +28.47% | Add |
| 19 | ALKS | Alkermes plc | +0.6% | — | Unchanged |
| 20 | ITCIEUR | Intra-cellular Therapies Inc | +0.6% | +4.08% | Add |
| 21 | XNCR | Xencor Inc | +0.5% | NEW | New buy |
| 22 | GH | Guardant Health Inc | +0.5% | +33.35% | Add |
| 23 | BCYC | Bicycle Therapeutics Plc-adr | +0.4% | +1.65% | Add |
| 24 | HELP | Cybin Inc | +0.4% | NEW | New buy |
| 25 | AVTX | Avalo Therapeutics Inc | +0.3% | NEW | New buy |
| 26 | NRIX | Nurix Therapeutics Inc | +0.3% | -3.09% | Trim |
| 27 | NMRA | Neumora Therapeutics Inc | +0.3% | +314.36% | Add |
| 28 | 430 | Terns Pharmaceuticals Inc | +0.2% | -8.58% | Trim |
| 29 | OLMA | Olema Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 30 | PLRX | Pliant Therapeutics Inc | +0.2% | — | Unchanged |
| 31 | AUTL | Autolus Therapeutics PLC | +0.2% | — | Unchanged |
| 32 | KRRO | Korro Bio Inc | +0.1% | +10.30% | Add |
| 33 | VIGL | Vigil Neuroscience Inc | +0.1% | +160.21% | Add |
| 34 | ETNBGBP | 89bio Inc | +0.1% | +20.60% | Add |
| 35 | ✓ | Zura Bio LTD | +0.1% | — | Unchanged |
| 36 | PYXS | Pyxis Oncology Inc | +0.1% | — | Unchanged |
| 37 | PRTA | Prothena Corporation plc | +0.1% | NEW | New buy |
| 38 | ALGS | Aligos Therapeutics Inc | +0.1% | NEW | New buy |
| 39 | FATE | Fate Therapeutics Inc | +0.1% | — | Unchanged |
| 40 | ANIP | Ani Pharmaceuticals Inc | +0.1% | +8.31% | Add |
| 41 | ALEC | Alector Inc | +0.1% | — | Unchanged |
| 42 | NTLA | Intellia Therapeutics Inc | 0% | +3.13% | Add |
| 43 | CNTX | Context Therapeutics Inc | 0% | — | Unchanged |
| 44 | NKTREUR | Nektar Therapeutics | — | -10.92% | Trim |
| 45 | IVVD | Invivyd Inc | 0% | — | Unchanged |
| 46 | RGLS | Regulus Therapeutics Inc | 0% | — | Unchanged |
| 47 | BRD1EUR | Mind Medicine Mindmed Inc | 0% | +15.75% | Add |
| 48 | IONS | Ionis Pharmaceuticals Inc | 0% | +10.00% | Add |
| 49 | RLMD | Relmada Therapeutics Inc | 0% | -45.35% | Trim |
| 50 | MGX | Metagenomi Therapeutics Inc | 0% | -34.05% | Trim |
According to official SEC Form 13F filings, Deep Track Capital, LP reported a total U.S. public equity portfolio value of $6.9B across 69 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, DVAX, GH) accounted for 10.6% of total reported equity market value during Q3 2024.
Top New Position Initiated
MBX
市值: $78.4M
Top Position Liquidated / Trimmed
AMGN
前期市值: $179.7M
During Q3 2024, Deep Track Capital, LP's top holdings by market value included ARGX (6.3%)、DVAX (4.4%)、GH (4.4%). The largest single position, ARGX, represented 6.3% of total portfolio value.
In Q3 2024, Deep Track Capital, LP made 64 total portfolio adjustments, initiating 11 new buys, adding to 21 positions, trimming 22 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.